Ingmar Jungner, 1* Santica M. Marcovina, 2 Göran Walldius, 3 Ingar Holme, 4 Werner Kolar, 1 and Eugen Steiner 1. Lipoproteins
|
|
- Winifred Atkins
- 6 years ago
- Views:
Transcription
1 Clinical Chemistry 44: (1998) Lipids and Lipoproteins Apolipoprotein B and A-I values in Swedish males and females, standardized according to the World Health Organization International Federation of Clinical Chemistry First International Reference Materials Ingmar Jungner, 1* Santica M. Marcovina, 2 Göran Walldius, 3 Ingar Holme, 4 Werner Kolar, 1 and Eugen Steiner 1 Serum concentrations of apolipoprotein (apo) B and apo A-I were measured from in a Swedish population sample of males and females, ages <20 to >80 years, using an automated immunoturbidimetric method calibrated against fresh pools of human serum and commercial calibrators. All values were recalculated in 1997 after calibration against the WHO- IFCC First International Reference Materials. The recalculation factor was for apo B, whereas for apo A-I, the correction was: y 0.989x The total CVs for both apo B and A-I were generally <7%. The mean value ( SD) for apo B was g/l in all males and g/l in all females. The mean apo A-I concentration was g/l in males 10% lower than in females ( g/l). The mean value of apo B increased up to 60 years of age in males and up to 70 years of age in females. apo A-I concentrations changed only slightly with age in both males and females. apo A-I concentrations among Swedes are nearly identical to those reported recently by two American studies and those obtained in a Finnish population sample. Mean apo B concentrations differ somewhat between the populations but mirror as expected differences in total 1 CALAB Research and CALAB Medical Laboratories, S:t Göran Hospital, S Stockholm, Sweden. 2 Department of Medicine, Northwest Lipid Research Laboratories, University of Washington, 2121 N 35th St., Seattle, WA King Gustaf V Research Institute, Karolinska Institute, S Stockholm, Sweden, and ASTRA HÄSSLE AB, S Mölndal, Sweden. 4 Institute for Medical Statistics, Ullevål Sykehus, P.O. Box 6, 0407 Oslo 4, Norway. *Author for correspondence. Fax ; ingmar.jungner@ stockholm.mail.telia.com. Received February 2, 1998; revision accepted May 14, cholesterol concentrations. The highest values were noted in Swedish subjects. The Swedish sample population is, to our knowledge, the largest describing the distribution of apo B and A-I in a general population of adult males and females of all ages determined with procedures standardized and traceable to the WHO- IFCC First International Reference Materials. In clinical practice, lipid, lipoprotein, or apolipoprotein (apo) 5 concentrations are measured to detect and diagnose lipid disorders (dyslipidemias), to assess the associated cardiovascular risk, and to decide subsequent treatments (1, 2). Sniderman and co-workers (3, 4) recently proposed that measurements of apo B should be used in routine clinical practice and should replace calculation of LDL-cholesterol by the Friedewald formula (5). These authors (3, 4), as well as ourselves and others (6 8), have argued that now that the measurements of apo B and apo A-I are standardized (9 12), they should be more widely used in clinical settings. Furthermore, apo B appears to give a more accurate predictive estimate of atherogenic risk than total cholesterol (TC) or LDL-cholesterol (13 15). apo B and apo A-I can also be determined with high precision and accuracy, and the measurements are easily automated (16, 17), reducing labor costs. In the past, a wider clinical use of apolipoprotein assays was limited by lack of standardization and, consequently, by lack of common population-based reference values. However, 5 Nonstandard abbreviations: apo, apolipoprotein; TC, total cholesterol; NHANES III, National Health and Nutrition Examination Survey III; AMORIS, Apolipoprotein-related Mortality Risk Study; TG, triglyceride; and CL, confidence limit. 1641
2 1642 Jungner et al.: Apolipoprotein B and A-I in a Swedish population recently two American studies have been published. Contois and co-workers (18, 19) presented reference intervals for apo B and apo A-I, primarily in adults, derived from the population-based Framingham Offspring Study. Bachorik et al. (20) measured the concentration of the two apos in Phase 1 ( ) of the Third National Health and Nutrition Examination Survey (NHANES III). The latter presented the distributions of apo A-I and apo B in persons 4 years of age or older, which were the first measured in a probability sample of the noninstitutionalized US civilian population. Both these American studies, as well as a Finnish study in 1995 by Leino et al. (21), used the new WHO-IFCC International Reference Materials as the basis for accuracy. All three investigations were, however, performed on a smaller number of subjects: 3824, , and 575, respectively. Since 1985, one of our group (I.J.) implemented automated methods for the determination of apo B and apo A-I, applying them in screening programs of large populations to improve information about the composition and degree of dyslipoproteinemias. Measurements of apo B and A-I in Swedes (6) and the basic data of the prospective study AMORIS (Apolipoprotein-related Mortality Risk) on Swedes were reported in 1992 (7). The aim of the present study after increasing more than threefold the investigated population and after recalculating earlier apolipoprotein measurements to the new WHO-IFCC standard was to provide a large basis for apo B and apo A-I reference intervals. Subjects and Methods Subjects Swedish males and females ( ) ranging in age from 20 years to 80 years were studied. The Swedish healthcare system has focused on general health screening performed during the last 20 years as a service to almost all employees of most companies, as well as to adult males and females in the general community (virtually all native Swedes). Calab has served as a major laboratory for the 3000 physicians involved in general healthcare. The present clinical material comprises all blood samples sequentially sent to Calab without any limitations because of age, possible diagnosis, or ongoing treatment with diet and/or drugs. Thus, no sample/subjects were excluded from this population study. Because our database does not contain any information about the use of drugs such as beta blockers and estrogens, the possible effects of such drugs on lipids and apo composition could not be analyzed in this study. The large majority of the subjects were subjectively healthy. The major part of the studied population comprised males and females years of age, as presented in our previous study (7). No samples were obtained from hospitalized patients or from subjects participating in clinical trials. Most subjects lived in the greater Stockholm area ( 20% were from other parts of Sweden). The original AMORIS population investigated during comprised subjects (7). The study has recently been extended to include data collected in The data base now comprises subjects ( males, mean SD age, years; and females, mean age, years). Here we describe findings from a subsample of the whole study population. These subjects had their first complete profile of apo B apo A-I TC triglycerides (TGs) taken simultaneously (n ; mean age, years for males and years for females). The subjects years of age are classified in decades. The classes 20 or 80 years of age have mean ages of and years, respectively; the number of males equaled the number of females. About two-thirds of the subjects (n ) were fasted overnight (n for males and n for females). The others had a light morning meal (n ), or the nutrition status was unknown (n ). methods The methods are the same as described earlier (6). apo B and A-I were determined by an immunoturbidimetric method according to Riepponen et al. (22), using polyclonal antisera from Orion Diagnostica (commercial assay). The company is one of the manufacturers that participated in the WHO-IFCC Standardization Program (9 12). TC was determined with the cholesterol oxidase/ peroxidase (CHOD-PAP) assay and TGs with the glycerol phosphate oxidase/peroxidase (GPO-PAP) assay, using enzymatic methods (reagents from Boehringer Mannheim) for the PRISMA instrument and from Bayer Diagnostics GmbH for the DAX instrument. All four methods were from the outset highly automated; from 1985 to 1992, the Multichannel AutoChemist -PRISMA (New Clinicon) was used and since 1993, the Multichannel DAX-96 (Technicon/Bayer Corp.) has been used. All analyzers were computerized with systems for automatic calibration. An extensive quality-control scheme was used throughout the study in determining serum apos. Table 1 shows the long-term precision data from materials used as controls. The total CV (CV total) was the same as reported earlier (6) for the initial ( ) part of the study: generally 7% for apo B, apo A-I, and TGs, and 3% for TC. For apo B and A-I, zero point and one-level calibration were done using fresh pools of human serum because of the lack of suitable calibrators for daily use. A pool of human serum was prepared each day from 300 clear samples from healthy controls. By using this large number of sera, the same mean values were expected (23). The technique was implemented from the start of the measurements in The pool material was replaced as calibrator as of 1993 by the commercially available Seronorm Lipid (Nycomed Pharma) supplemented by the Apolipoprotein Calibration Set SPQ (Incstar Corp.) to maintain stable quality performance.
3 Clinical Chemistry 44, No. 8, Year a No. of months Controls, n b Table 1. Long-term precision data for apolipoproteins. apo B Concentration, g/l Total CV, % Target value Controls, n b apo A-I Concentration, g/l Total CV, % Target value Instrument Fresh pools of human serum 1987 c Prisma 1988 c Prisma 1989 c Prisma Prisma Prisma Prisma DAX DAX DAX DAX DAX DAX-96 Deep-frozen pools of human serum Prisma Prisma Prisma Prisma DAX DAX-96 Seronorm Lipid Prisma Prisma DAX DAX DAX DAX d d d d d DAX-96 Beckman Triad LINK level I DAX DAX d d d d DAX DAX d d d d DAX-96 Beckman Triad LINK level DAX DAX d d d DAX DAX-96 Beckman Triad LINK level DAX d d d d d DAX DAX d d d d d DAX-96 a Calibrators: , fresh pools of human sera; , Seronorm Lipid; , Apo B and Apo A-1 Calibration/Control Set (SPQ Test System). b Number of analyses. c Data cited from Jungner et al. (6). d New batch.
4 1644 Jungner et al.: Apolipoprotein B and A-I in a Swedish population Table 2. Profile data of groups in the study. A. Selected percentiles for apo B (g/l) distribution. Percentile Age, years Sex n a Mean SD 5th 10th 25th 50th 75th 90th 95th All M F M F M F M F M F M F M F M F M F B. Selected percentiles for apo A-I (g/l) distribution. Percentile Age, years Sex Mean SD 5th 10th 25th 50th 75th 90th 95th All M F M F M F M F M F M F M F M F M F C. Means and SDs b for apo B/A-I ratio, TC (mmol/l), and TGs (mmol/l). Age, years Sex apo B/A-I, mean SD TC, mean SD TGs, mean SD All M F M F M F M F M F M F M F M F M F a Subpopulation (n ) of NEW AMORIS, , divided by sex and age. The number of subjects in each decade is the same throughout the table. b Selected percentiles (log-normal distribution) for different sex and age groups can be requested from corresponding author.
5 Clinical Chemistry 44, No. 8, Daily samples from fresh or frozen pools of human sera were used as controls; since 1993 commercially available materials like Seronorm Lipid and Beckman control sera were utilized (Triad LINK level 1 3). The inaccuracy for TC and TGs was checked against material from the National Institute of Standards and Technology, Gaithersburg, MD, or by analyses performed by lipid reference laboratories certified by the CDC. Traceability to the WHO-IFCC International Reference Materials. Recalculation of collected apolipoprotein data was done in 1997 in collaboration with the Northwest Lipid Research Laboratories, University of Washington, Seattle, WA. This laboratory was the one that organized and coordinated the IFCC standardization program (9 12). They provided Calab with three concentrations of their apo B and apo A-I fresh-frozen quality-control samples prepared in-house, with values assigned against the WHO-IFCC Reference Materials. During 5 days, 36 determinations of apo A-I and apo B were performed on each quality-control sample, and data were sent to Northwest Lipid Research Laboratories for statistical evaluation. On the basis of the results of this analysis, a correction factor of for apo B and the correction y 0.989x for apo A-I was used to ensure that values were traceable to the WHO-IFCC International Reference Materials. Accredited laboratory facilities. All analyses were done at Calab Medical Laboratories, Stockholm, Sweden. For almost every determination of apos and lipids, 20 other laboratory analyses were performed as a basis for clinical evaluation. In 1994, the laboratory received an international accreditation according to European Norm by the Swedish Board for the Technical Accreditation (Borås, Sweden). Calab also received a Statement of Good Laboratory Practice compliance (Läkemedelsverket, Uppsala, Sweden) in The laboratory performed analyses in 1996 and is accredited in clinical chemistry, hematology, immunology, and microbiology. statistical analysis Data are presented as means (and SDs), 95% ranges, medians, or selected, theoretically calculated log-normal percentile limits. For between-group mean differences, 95% confidence limits (95% CL) are used. Results mean values and distributions of apolipoproteins The results of the first complete profile data (apo B, apo A-I, apo B/A-I ratio, TC, and TGs) from subjects are shown in Table 2. Selected percentile values of apo B and apo A-I as well as means and SDs of the other variables for males and females in each decade and in the total population are presented. These values were obtained by pooling results from fasting and nonfasting subjects, as in NHANES (20). The mean apo B concentration (Table 2A) was g/l in males (n ) significantly higher than the mean for the females [ g/l; 95% CL for difference, (0.086, 0.094)]. The mean apo A-I concentration (Table 2B) in males was g/l 10% lower than in females [ g/l; 95% CL for difference, 0.15 (0.148, 0.152)]. apo B and A-I concentrations showed an almost gaussian distribution. For the various age and sex strata, the differences between the mean and the median values ranged from 0.03 to 0.05 g/l (apo B) and from g/l (apo A-I), suggesting that the distributions of apo B and A-I were virtually gaussian. The mean apo B/A-I ratio (Table 2C) was in males and in females [95% CL for difference, 0.16 (0.157, 0.163)], whereas the 95% interval was in males and in females, including all ages. The distributions of the apo B/A-I ratio were also virtually gaussian, the differences between the mean and the median values ranging from 0.02 to 0.05 (data not shown). apo b and apo a-i in fasting and nonfasting subjects A comparison between samples collected from subjects reported to be in a fasting state or in nonfasting state showed for apo A-I no difference, whereas the values for apo B were slightly lower. The maximal deviation was 3.3% for apo A-I and 7.7% for apo B (data not shown). apo b and apo a-i by age Median apo B concentrations in adult males were g/l, and the increase continued from those years of age and tended to decrease after age 60 (Fig. 1A). The median apo B concentrations in adult females were g/l, and the increase continued in those in the age group years, with a more pronounced increase in the age group years, and then decreased after age 70 (Fig. 1A). In both males and females, apo B ultimately reached about the same concentration (1.36 g/l for males and 1.38 g/l for females); however, in males this occurred 10 years earlier than in females. apo B values in younger age cohorts were higher among males than among females, whereas the cohorts at 60 years of age showed a reverse relation. The 95% interval for apo B was g/l for males and g/l for females, including all ages. Median apo A-I concentrations in adult males ranged from 1.30 to 1.36 g/l, with only a slight continuous increase from 20 to 59 years, followed by a plateau at years, and then a decrease at 70 years (Fig. 1B). Median apo A-I concentrations in adult females ranged from 1.45 to 1.52 g/l, and there was a first plateau in the age range years, then an increase up to 59 years, followed by a second plateau in the age range years, and a decrease at 70 years (Fig. 1B). The 95% interval for apo A-I was g/l for males and g/l for females, including all ages. The highest
6 1646 Jungner et al.: Apolipoprotein B and A-I in a Swedish population apo B/A-I ratio for males was seen in males years old, whereas the highest ratio for females was obtained in those years old (Fig. 1C). tc and tg values The mean TC (5.9 mmol/l) was the same for males and females (Table 2C). There was no difference between fasting and nonfasting TC values (data not shown). The median TG concentration, including results from all individuals in fasting or nonfasting states, was 1.35 mmol/l for males (95th percentile, 3.64 mmol/l) and 1.04 mmol/l (95th percentile, 2.56 mmol/l) for females (data not shown); Table 2C shows mean values. The fasting median TG (data not shown) for males was 1.29 mmol/l (95th percentile, 3.44 mmol/l), and 1.00 mmol/l (95th percentile, 2.42 mmol/l) for females; fasting mean TG values are given for comparison (Table 3) and were 1.57 and 1.18 mmol/l for males and females, respectively. The difference for TGs between males and females was significant, at P comparison with other population studies traceable to the who-ifcc This Swedish population sample was compared (Table 3) with characteristics for three other population samples traceable to the WHO-IFCC First International Reference Materials: two American (the Framingham Offspring Study (18, 19) and the NHANES III (20)) and one Finnish (21). These populations are from different ethnic origins and differ in sample size and TC concentrations. Their mean age was about the same. If differences in TC concentrations among the population samples are taken into account, the concentrations and percentile distributions of apo B are very similar and of apo A-I are almost identical. Fig. 1. Differences in apo B and apo A-I concentrations and ratios according to age group. Median concentrations (g/l) for apo B (A) and apo A-I (B) together with apo B/A-I ratio (C) at each 10-year interval of males and females. The classes 20 or 80 years have mean ages of and years, respectively. Discussion The present study is the first large epidemiological study applying automated apo methods over several years to the health screening of males and females covering wide age ranges. However, compared with previously published population studies (18 20), our results have always been obtained on fresh samples, thus avoiding possible effects of long-term storage and of freezing and thawing of the samples. In 1992 (6), we presented the first large population report on apo determinations in males and females. Now we have corrected our original results, so that they are traceable to the WHO-IFCC Reference Materials. Thus, our present results are directly comparable with those obtained in recently presented population studies. Determinations of apos may provide a more specific characterization of the type of lipoprotein abnormality, thus leading to a more accurate prediction of the risk of coronary artery disease than that made using the TC, TG, and HDL values alone, as discussed elsewhere (3, 4). To establish whether apo B and A-I, as well as the ratio apo B/A-I, are better predictors of atherogenic risk than TC and TGs, the AMORIS subjects (7) will be
7 Clinical Chemistry 44, No. 8, Table 3. Characteristics of the Swedish population sample compared with other recently reported population samples traceable to the WHO-IFCC First International Reference Materials. Percentile 10th 25th 50th 75th 90th Mean SD apo B, g/l Males SWE a FIN FOS/USA USA Females SWE FIN FOS/USA USA apo A-I, g/l Males SWE FIN FOS/USA USA Females SWE FIN FOS/USA USA n Age, years b TC, mmol/l b ftgs, mmol/l b Males SWE c FIN (range) d FOS/USA USA e 5.08 e 1.42 e Females SWE c FIN (range) d FOS/USA USA e 5.08 e 1.42 e a SWE, Swedish population sample; FIN, Finnish sample (21); FOS/USA, Framingham Offspring Study (18,19); USA, NHANES III (20); and f, fasting. b Mean SD. c For comparison with Finnish sample. Males, after logarithmic transformation; females, after logarithmic transformation. d After logarithmic transformation. e Not specified or sex-divided. monitored over an extended period of time. Another major question that remains to be answered is how much apo B and apo A-I add to the determination of TC and TGs in prediction of total fatal risk. A second report of the AMORIS study, with extended mortality data in relation to initial TC and TG and especially to initial apo B and apo A-I concentrations, is under preparation. Our present study shows that the measurements of apo B and apo A-I were performed with good precision and accuracy throughout the whole observation period. As controls, pools of both fresh and frozen samples of human serum (Table 1) were used. These gave results similar to those found by other authors (19, 21, 24). Of our originally presented data (6, 7), only minor corrections for both apo B and A-I were needed to harmonize the data to be traceable to the WHO-IFCC International Reference Materials. The errors of the methods are of the same order of magnitude or better than those suggested by Marcovina and Albers (25). They recommended that the between-run values should be 8%, and optimally 5%. Bachorik et al. (20) report that the CVs for apo A-I and B averaged 6% throughout the NHANES III study. Recent CV estimates of the overall biological variation of apo B and apo A-1 were 6 7% (24). In our study, there was virtually no difference (apo A-I) or only a slight (apo B) difference, when we compared values obtained in fasting state with
8 1648 Jungner et al.: Apolipoprotein B and A-I in a Swedish population values obtained in individuals having taken a light meal. Although the data were obtained from different individuals, the total number of subjects was large enough in each group of individuals to support the notion that a light meal does not change apo B or apo A-I concentrations (26 28). Bachorik et al. (20) also found in the NHANES study that there were no significant differences in apo B or apo A-I between fasting or nonfasting subjects; they therefore combined the data from both groups. Thus, apos may be regarded as robust measurements, at least regarding sampling conditions. This has considerable practical impact, both for the patient often traveling far to get his or her blood taken and for the physician in terms of the interpretation of the data. Whereas apo B values for both sexes clearly increased with age, apo A-I values showed only minor age-related variation. Males have higher apo B values than females up to age 60. After menopause, apo B concentrations in females continued to rise. Females had 10% higher apo A-I concentrations than males in all age groups. Similar age-related values for apo B and apo A-I were observed in 1992 (6). The present results for apo A-I are in close agreement with the 10% difference also found in the NHANES III Survey (20) and the 13% found in the Framingham Offspring Study (19) and the Finnish study (21) (Table 3). The results reported in these studies were all obtained by turbidimetric analysis with the exception of the NHANES III where rate immunonephelometry was used most of the time (they changed from a radial immunoassay when automated methods were becoming more widely used). The Framingham study used turbidimetric assay reagents and calibrators from Incstar Corp. The Swedish and Finnish studies both used the same turbidimetric method (22) and the same supplier of reagents (Orion Diagnostics). The percentile distributions for the four studies were rather similar (apo B) and nearly identical (apo A-I). apo B is positively correlated with TC (6, 18, 21); therefore, in accordance with the cholesterol data, mean apo B was highest for the Swedes and lowest for the Americans. Mean apo A-I concentrations were virtually the same for all four population samples, with ranges of g/l for males and g/l for females (Table 3). The often conflicting findings reported earlier for apo analysis have been mainly ascribed to differences in methodological approaches, sample handling and storage, and especially to the previous lack of common reference materials to which the calibration of the methods could be referred. In view of the results from the latest investigations, which all rely on the WHO-IFCC International Reference Materials, it can be concluded that the WHO-IFCC standardization has attained its purpose and that it is now possible to establish that there are only minor differences between different populations. Bachorik et al. (20) compared the results from their survey with the Framingham Offspring Study and reported only small differences between different ethnic groups. Several authors, especially after the introduction of the WHO-IFCC Reference Materials, have discussed and suggested cutpoints for apo B (4, 8, 18, 20) and apo A-I (8, 19, 20) that may be used to assess coronary heart disease risk. Bachorik at al. (20) determined apo B concentrations in adults, ages 20 years, categorized by the National Cholesterol Education Program risk levels for LDL-cholesterol. They conclude that the question of whether apo B might eventually be used instead of LDL-cholesterol as the basis for assessing risk for coronary heart disease remains open. Because apo B varies with age and apo A-I varies with sex, age- and sexstandardized values should be used as markers for cardiovascular risk. However, the introduction of new markers for atherogenic risk that may be used instead of the established and accepted LDL and HDL determinations makes this new approach difficult from a practical standpoint. Too many cutoff values create practical problems related to lack of simplicity. Instead of using sex- and age-standardized values, the alternative approach would be to choose a few cutoff values and evaluate whether such values are clinically significant. We are in the process of analyzing AMORIS data relating baseline apo B, apo A-I, TC, and TG values to final risk/fatal myocardial infarction, using the approach of dichotomizing risk in relation to age and sex, as well as by age-and sexstandardized algorithms. The recommended cutoff value should be proven to discriminate future coronary heart disease risk in a stringent, predictive, and possibly simple way. The final decision of how to best define relevant risk and cutoff values must await outcome studies like AMORIS. This work was supported by grants from Gunnar and Ingmar Jungner Foundation for Laboratory Medicine and from Bure Hälsa & Sjukvård Ltd, Stockholm, to Calab Research. References 1. European Atherosclerosis Society: international task force for prevention of coronary heart disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992;2: The Expert Panel. Summary of the second report of the National Cholesterol Education Panel (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269: Sniderman AD. To (measure apo)b or not to (measure apo)b: a critique of modern medical decision-making. Clin Chem 1997;43: Sniderman AD, Cianflone K. Measurement of apolipoproteins: time to improve the diagnosis and treatment of atherogenic dyslipoproteinemias [Editorial]. Clin Chem 1996;42: Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18: Jungner I, Walldius G. Holme I, Kolar W, Steiner E. Apolipoprotein B, A-I in relation to serum cholesterol and triglycerides in Swedish males and females. Int J Clin Lab Res 1992;21:
9 Clinical Chemistry 44, No. 8, Walldius G, Jungner I, Kolar W, Holme I, Steiner E. High cholesterol and triglyceride values in Swedish males and females: increased risk of fatal myocardial infarction. First report from the AMORIS (Apolipoprotein-related Mortality Risk) Study. Blood Press 1992; 1(Suppl 4): Bhatnagar D, Durrington PN. Measurement and clinical significance of apolipoprotein A-I and B. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing. Washington, DC: AACC Press, 1997: Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 1991;37: Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 1992;38: Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993;39: Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994;40: Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994;343: Lamarche B, Moorjani S, Lupien, PJ, Cantin B, Bernard P-M, Dagenais GR, Despres JP. Apolipoprotein A-I, B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation, 1996;94: Rosseneu M, Fruchart JC, Bard JM, Nicaud V, Vinaimmont N, Cambien F, et al. Plasma apolipoprotein concentrations in young adults with parental history of premature coronary heart disease and in control subjects. The EARS study. Circulation 1994;89: Labeur C, Shephard J, Rosseneu M, Immunological assays of apolipoproteins in plasma: methods and instrumentation. Clin Chem 1990;36: Stein E A. Clinical significance and measurement of apolipoproteins A-1 and B. In: Rifai N, Warnick GR, eds. Laboratory measurement of lipids, lipoproteins and apolipoproteins. Washington, DC: AACC Press, 1994: Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42: Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42: Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B, AI distributions in the United States, : results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997;43: Leino A, Impivaara O, Kaitsaari M, Järvisalo J. Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein (a) in a Finnish sample. Clin Chem 1995;41: Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoprotein A-I and B in serum. Scand J Clin Lab Investig 1987;47: Cembrowski GS, Chandler EP, Westgard JO, Assessment of average of normals quality control procedures and guidelines for implementation. Am J Clin Pathol 1984;81: Marcovina SM, Gaur VP, Albers JJ. Biological variability of cholesterol, triglyceride, low-and high-density lipoprotein cholesterol, lipoprotein (a) and apolipoproteins A-I and apo B. Clin Chem 1994;40: Marcovina SM, Albers JJ. Apolipoprotein assays: standardization and quality control. Scand J Clin Lab Investig 1990;50(Suppl 198): Rifai N, Dufour DR, Cooper GR. Preanalytical variation in lipid, lipoprotein, and apolipoprotein testing. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing. Washington, DC: AACC Press, 1997: Seishima M, Noma A, Torizawa H, Muto Y. Changes of serum apolipoprotein levels after oral administration of fat in human subjects. Atherosclerosis 1988;73: Rifai N, Merill JR, Holly RG. Postprandial effect of a high fat meal on plasma lipid, lipoprotein cholesterol and apolipoprotein measurements. Ann Clin Biochem 1990;27:
ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients
ARTICLE Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients Baruch S. Ticho, MD, PhD; Ellis J. Neufeld, MD, PhD; Jane W. Newburger, MD, MPH; Neil Harris,
More informationReference Materials for the Standardization of the Apolipoproteins A-I and B, and Lipoprotein(a)
Reference Materials for the Standardization of the Apolipoproteins A-I and B, and Lipoprotein(a) Francesco Dati 1, Jillian Tate 2 1 TÜV Rheinland Product Safety GmbH, Am Grauen Stein, D-51105 Cologne,
More informationAtherosclerosis 207 (2009) Contents lists available at ScienceDirect. Atherosclerosis
Atherosclerosis 207 (2009) 200 207 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis Levels of lipids and apolipoproteins in three cultures
More informationKatsuyuki Nakajima, PhD. Member of JCCLS International Committee
Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham
More informationAtherosclerosis 213 (2010) Contents lists available at ScienceDirect. Atherosclerosis
Atherosclerosis 213 (2010) 299 305 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis Inflammatory markers, lipoprotein components and risk
More informationFriedewald formula. ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5. Friedewald formula. Friedewald formula
Friedewald formula 1 1 1,2 ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5 Friedewald formula Friedewald formula 2003 99 Friedewald formula Colorimetric method
More informationLipid Profile Analysis of Aircrew
Original Article Lipid Profile Analysis of Aircrew Sampath S *, Richa + ABSTRACT Most laboratories including all our Armed Forces Centers, estimate Low Density Lipoproteins Cholestorol (LDL-C) levels with
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationPatricia C. Fallest-Strobl, 1 Elin Olafsdottir, 2 Donald A. Wiebe, 1 and James O. Westgard 1 * Lipoproteins
Clinical Chemistry 43:11 2164 2168 (1997) Lipids and Lipoproteins Comparison of NCEP performance specifications for triglycerides, HDL-, and LDL-cholesterol with operating specifications based on NCEP
More informationLipoprotein (a): Is it important for Friedewald formula?
ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry
More information. Non HDL-c : Downloaded from ijdld.tums.ac.ir at 18:05 IRDT on Friday March 22nd Non HDL LDL. . LDL Non HDL-c
208-23 (2 ) 0 389 -. Non HDL * Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209 Non HDL : LDL.. 5 3277 :.. odds ratio Chi-Square %3/9 Non HDL-C %2 LDL-C. %3 : Non-HDL-C LDL-C. (CI
More informationComparison of two assays for measuring LDL cholesterol
Clinical Chemistry 43:6 1040 1047 (1997) Lipids and Lipoproteins Comparison of two assays for measuring LDL cholesterol Anirban Maitra, Shaina V. Hirany, and Ishwarlal Jialal* The purpose of this study
More informationHigh-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationApolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationFamilial combined hyperlipidemia (FCH) was first described
Clinical Investigation and Reports Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a 5-Year Follow-Up Study Mario J. Veerkamp, MD; Jacqueline de Graaf, MD, PhD; Jan C.M.
More informationSeparation of HDL Particles by Immunoprecipitation
Sun Diagnostics, LLC Separation of HDL Particles by Immunoprecipitation Rae-Anne Nguyen and John H. Contois 13 Introduction We all know that HDL cholesterol concentration is inversely associated with coronary
More informationThe Second Report of the Expert Panel on Detection,
Blood Cholesterol Screening Influence of State on Cholesterol Results and Management Decisions Steven R. Craig, MD, Rupal V. Amin, MD, Daniel W. Russell, PhD, Norman F. Paradise, PhD OBJECTIVE: To compare
More informationTina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk
Tina-quant Lipoprotein (a) Gen. 2 For accurate and reliable assessment of cardiovascular risk cobas modular platform Flexible configurations for tailormade solutions With the cobas modular platform (cobas
More informationEvaluation of Calculated Low-Density Lipoprotein Against a Direct Assay
Evaluation of Calculated Low-Density Lipoprotein Against a Direct Assay Navapun Charuruks MD*, Anna Milintagas BSc** * Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University **
More information(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)
cobas b system - performance evaluation Study report from a multicenter evaluation of the new cobas b system for the measurement of HbAc and lipid panel Introduction The new cobas b system provides a point-of-care
More informationThe Association of Apolipoprotein B and Low Density Lipoprotein with Cardiovascular Risk Factors in the Thai Population
The Association of Apolipoprotein B and Low Density Lipoprotein with Cardiovascular Risk Factors in the Thai Population Rungroj Krittayaphong MD*, Chunhakasem Chotinaiwatarakul MD**, Charuwan Kangkagate
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),
More informationTraceable lipoprotein counting for Cardiovascular disease risk assessment Vincent DELATOUR, PhD
Traceable lipoprotein counting for Cardiovascular disease risk assessment Vincent DELATOUR, PhD 1 The need for primary methods VIM 2008 : Primary reference measurement procedure : reference measurement
More informationEstimation of glucose in blood serum
Estimation of glucose in blood serum Enzymatic estimation of glucose uses a reagent containing two enzymes and a chromogen. Glucose oxidase catalyses the oxidation of glucose to gluconolactone with the
More informationImproving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study
Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study Marianne Benn, Børge G. Nordestgaard, Gorm Boje Jensen, Anne Tybjærg-Hansen
More informationNon-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
Diabetologia (2011) 54:73 77 DOI 10.1007/s00125-010-1945-z SHORT COMMUNICATION Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus S. van Dieren & U. Nöthlings & Y.
More informationThe apob/apoa-i ratio: a strong, new risk factor for. cardiovascular disease and a target for lipidlowering
Journal of Internal Medicine 2006; 259: 493 519 doi:10.1111/j.1365-2796.2006.01643.x SYMPOSIUM The apob/apoa-i ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering
More informationLIPID-ATHEROSCLEROSIS LABORATORY SERVICES GUIDE
LIPID-ATHEROSCLEROSIS LABORATORY SERVICES GUIDE Revised 3/2014 LIPID-ATHEROSCLEROSIS LABORATORY SERVICES GUIDE For questions concerning protocol and assay development, validation of results, etc., please
More informationASSESMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL BY HOMOGENEOUS ASSAY VERSUS FRIEDEWALD S EQUATION - A STUDY OF 50 CASES.
Volume: I: Issue-1 May-July -2010 ASSESMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL BY HOMOGENEOUS ASSAY VERSUS FRIEDEWALD S EQUATION - A STUDY OF 50 CASES. Lincy Jacob 1, Ravikanth Medikonda 2, Piyush
More informationCoverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests
Coverage Guidelines NMR LipoProfile and NMR LipoProfile -II Tests Disclaimer: Please note that Baptist Health Plan updates Coverage Guidelines throughout the year. A printed version may not be most up
More informationStandardization of Apolipoprotein B and A-I Measurements
CLIN. CHEM. 35/7, 1357-1361 (1989) Standardization of Apolipoprotein B and A-I Measurements John J. Albers and Santica M. Marcovina2 Apolipoprotein B, the major protein of low-density lipoprotein, and
More informationEpidemiology. Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events
Epidemiology Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events Samia Mora, MD, MHS; Nader Rifai, PhD; Julie E. Buring, ScD; Paul M Ridker, MD, MPH
More informationStudy of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease
Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,
More informationTechnical Bulletin. Cholesterol Reference Method Laboratory Network (CRMLN) Overview. TB Rev. 0
Technical Bulletin Reference Method Laboratory Network (CRMLN) Overview TB000020 Rev. 0 Reference Method Laboratory Network (CRMLN) - General Information With guidance from the US Centers for Disease Control
More informationLipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures
Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic
More informationCurrent Challenges in CardioMetabolic Testing. Kenneth French, Director of Clinical Operations
Current Challenges in CardioMetabolic Testing Kenneth French, Director of Clinical Operations Disclosers Employee at VAP Diagnostics Laboratory Outline Cardiometabolic Disease: Current Challenges and Methodology
More informationAccuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips
Accuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips Sponsored by Arthur Roberts, MD of The Living Heart Foundation The Living Heart
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationCalibration of High-Density Lipoprotein Cholesterol Values From the Korea National Health and Nutrition Examination Survey Data, 2008 to 2015
Original Article Clinical Chemistry Ann Lab Med 217;37:1-8 https://doi.org/1.3343/alm.217.37.1.1 ISSN 2234-386 eissn 2234-3814 Calibration of High-Density Lipoprotein Cholesterol Values From the Korea
More informationRenal insufficiency, mortality and myocardial infarction
From The Institute of Environmental Medicine Karolinska Institutet, Stockholm, Sweden Renal insufficiency, mortality and myocardial infarction Martin Holzmann Stockholm 2008 1 All previously published
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationNon-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017
Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required
More informationMartin/Hopkins Estimation, Friedewald and Beta- Quantification of LDL-C in Patients in FOURIER
TAP TO GO BACK TO KIOSK MENU Seth S. Martin, M.D., M.H.S., Robert P. Giugliano, M.D., S.M., 2 Sabina A. Murphy, M.P.H., 2 Scott M. Wasserman, M.D., 3 Peter S. Background Evolocumab, a fully human monoclonal
More informationNorthwest Lipid Metabolism and Diabetes Research Laboratories, Division of Metabolism,
Lp(a) Measurements for Clinical Application Santica M Marcovina and John J Albers Northwest Lipid Metabolism and Diabetes Research Laboratories, Division of Metabolism, Endocrinology, and Nutrition, Department
More informationEffects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome A randomized, double-blind,
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationLDL . (LDL) Downloaded from ijdld.tums.ac.ir at 12:38 IRST on Friday February 1st 2019 LDL LDL NCEP-ATP-III (LDL) :
197-207 (2 ) 10 1389 -. 2 1 1* :.. 352 :... (TG). (). -.(r= 0/95) :. TG. NCEP-ATP-III. :. () : -1-2 1593748711 : ronakn2000@yahoo.com : 88942661-5 09124135284 ... : 198.[4]. 1990 -. C.[4]. NCEP.[4]...
More informationpatient-oriented and epidemiological research
patient-oriented and epidemiological research Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese Kuo-Liong Chien, 1, *,, Hsiu-Ching Hsu, Ta-Chen
More information6to. Congreso Virtual de Cardiología - 6th Virtual Congress of Cardiology
Index > 6VCC > Epidemiology and Cardiovascular Prevention Brief Communication Accuracy of the Friedewald Formula Being in Significant Relation to Total Cholesterol Rudolf Gaško, Caio Mauricio Mendes de
More informationCOMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI
COMPARISON OF APOLIPOPROTEIN CONCENTRATIONS AND VALUES OF APOB:APOAI WITH TRADITIONAL LIPID MEASURES IN WOMEN DIAGNOSED WITH ACUTE CORNONARY SYNDROMES A PRELIMINARY REPORT. Magdalena Krintus, Katarzyna
More informationRaising high-density lipoprotein cholesterol: where are we now?
European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationDYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid
Malaysian Journal of Medical Sciences, Vol. 11, No. 1, January 2004 (44-51) ORIGINAL ARTICLE DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationMethod-Dependent Variations in the Stability of Apolipoprotein B in a Stabilized Liquid Reference Material
CLIN. CHEM. 40/5, 716-722 (1994) #{149} Lipids and Lipoproteins Method-Dependent Variations in the Stability of Apolipoprotein B in a Stabilized Liquid Reference Material Joanne V. Mel, Mary K. Powell,
More informationApolipoprotein B and non-high-density lipoprotein cholesterol. and risk of coronary heart disease in Chinese
Apolipoprotein B and non-high-density lipoprotein cholesterol and risk of coronary heart disease in Chinese Chien et al. Apolipoprotein B in Chinese Kuo-Liong Chien, 1, * Hsiu-Ching Hsu, Ta-Chen Su, Ming-Fong
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationLIPOPROTEIN PROFILING
LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationDepartment of Biochemistry, GMC, Jagdalpur, Chhattisgarh. 2
Page255 SERUM APOLIPOPROTEIN AI & B, LIPOPROTEINS, LIPIDS LEVELS IN INDIAN PATIENTS WITH ANGIOGRAPHICALLY DEFINED CORONARY ARTERY DISEASE N.S. Dange *1, Abhay Nagdeote 2, kedar Deshpande 3 1 Department
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationBiological Variability of Cholesterol, Triglyceride, Low- and High-Density Lipoprotein Cholesterol, Lipoprotein(a), and Apolipoproteins A-I and B
CLIN CI-IEM 4/4, 574-578 (1994) #{149} Lipids and Lipoproteins Biological Variability of Cholesterol, Triglyceride, Low- and High-Density Lipoprotein Cholesterol, Lipoprotein(a), and Apolipoproteins A-I
More informationORIGINAL ARTICLE. APO B/APO AI Ratio with Coronary Artery Disease with Normal Lipid Profile in the Indian Population
22 Journal of The Association of Physicians of India Vol. 65 October 2017 ORIGINAL ARTICLE APO B/APO AI Ratio with Coronary Artery Disease with Normal Lipid Profile in the Indian Population Ranjan Modi
More informationLDL How Low can (should) you Go and be Safe
LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and
More informationNonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?
Papers in Press. Published January 19, 2016 as doi:10.1373/clinchem.2015.247866 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2015.247866 Clinical Chemistry 62:3 000 000
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationFor In Vitro Diagnostic Use. Rx Only. Reviewed by Date Reviewed by Date
SYNCHRON System(s) Chemistry Information Sheet 2015 Beckman Coulter, Inc. All rights reserved. HDLD HDL Cholesterol 650207 For In Vitro Diagnostic Use ANNUAL REVIEW Rx Only Reviewed by Date Reviewed by
More informationEvaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients
Clinical Biochemistry 34 (2001) 593 602 Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients Eleni Bairaktari a, *, Moses Elisaf b, Christos Tzallas
More informationASSOCIATION BETWEEN BODY MASS INDEX, LIPID PEROXIDATION AND CORONARY LIPID RISK FACTORS IN HYPOTHYROID SUBJECTS
ASSOCIATION BETWEEN BODY MASS INDEX, LIPID PEROXIDATION AND CORONARY LIPID RISK FACTORS IN HYPOTHYROID SUBJECTS V Shanmugapriya, PK Mohanty, D Anil Kumar Department of Biochemistry, Vinayaka Missions Medical
More informationHDL CHOLESTEROL. 01 English - Ref.: 13. Ref.:13. Insert
HDL CHOLESTEROL Insert Ref.:13 Intended use. System for selective precipitation of Low and Very Low Density Lipoproteins (LDL and VLDL) and HDL cholesterol measurement in the supernatant, by an end point
More informationReference Values for Apolipoprotein A-I and Apolipoprotein B in Serum Still Depend on Choice of Assay Techniques
Boerma et al.: Reference values of apolipoprotein A-I and B depend on assay technique 923 Eur. J. Clin. Chera. Clin. Biochem. Vol. 32, 1994, pp. 923-927 1994 Walter de Gruyter & Co. Berlin New York Reference
More informationApolipoprotein A1 (Apo A1) ELISA
Package Insert Apolipoprotein A1 (Apo A1) ELISA 1 x 96 Wells For Research Use Only (RUO). Not for use in clinical, diagnostic or therapeutic procedures. v. 1.0 Eagle Biosciences, Inc. 20A Northwest Blvd.,
More informationRecently reported clinical trials have provided strong
Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions The Atherosclerosis Risk in Communities (ARIC)
More informationComparison of a Homogeneous Assay With a Precipitation Method for the Measurement of HDL Cholesterol in Diabetic Patients
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Comparison of a Homogeneous Assay With a Precipitation Method for the Measurement of HDL Cholesterol in Diabetic Patients TONNY JENSEN, MD
More informationPattern of plasma lipoprotein (a) in Sudanese patients with coronary
Pattern of plasma lipoprotein (a) in Sudanese patients with coronary artery disease Mansour Eltahir Farah 1, Khairia Eltahir Abdullah 2, Huda HM Elhassan 3, Mohammed O EH Gadour 1, Mohammed Saeed Alkhaleefa
More informationPage 1. Disclosures. Background. No disclosures
Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen
More informationKeywords: Type 2 DM, lipid profile, metformin, glimepiride ABSTRACT
Human Journals Research Article September 2015 Vol.:4, Issue:2 All rights are reserved by K. Saravanan et al. Effects of Monotherapy and Combination Therapy Involving Metformin and Glimepiride on HbA1c
More informationHBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS
Original Article HBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS Chintamani Bodhe*, Deepali Jankar**, Tara Bhutada***, Milind Patwardhan****, Mrs Varsha Patwardhan***** ABSTRACT
More informationFor personal use only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Apolipoprotein Mature HDL particle Unesterified cholesterol Cholesteryl ester Copyright Dowden Health Media For personal
More informationTherapeutic Lifestyle Changes and Drug Treatment for High Blood Cholesterol in China and Application of the Adult Treatment Panel III Guidelines
Therapeutic Lifestyle Changes and Drug Treatment for High Blood Cholesterol in China and Application of the Adult Treatment Panel III Guidelines Paul Muntner, PhD a,b,, Dongfeng Gu, MD c, Robert F. Reynolds,
More informationResearch Article Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?
Hindawi Publishing Corporation Cholesterol Volume 13, Article ID 52948, 6 pages http://dx.doi.org/.1155/13/52948 Research Article Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationASSESSMENT OF INSULIN RESISTANCE AND Apo B / Apo A1 RATIO IN TYPE II DIABETES PATIENTS
ORIGINAL ARTICLE ASSESSMENT OF INSULIN RESISTANCE AND Apo B / Apo A RATIO IN TYPE II DIABETES PATIENTS 2 3 RP.Sathvika, Philips Abraham, R.Sudha, Evangeline Jones Background: Insulin resistance (IR) is
More informationDiabetes Care 31: , 2008
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S. KHIET C. HOANG, MD HELI GHANDEHARI VICTOR
More information1. Reagent Store at 2-8 ºC.
LDL Insert Ref.:146 Intended use. System for direct quantitative determination of low density lipoprotein (LDL) in serum or plasma samples. Professional use. [For in vitro diagnostic use.] Test principle.
More informationGeneral Chemistry Scheme Guide
General Chemistry Scheme Guide Copyright WEQAS. All rights reserved. No part of this document may be reproduced or utilised in any form without permission from WEQAS Contents. Scheme details and repertoire.....
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationValidation of an ELISA development kit for apolipoprotein B measurement in dried blood spots. Geeta N Eick, Paul Kowal, J Josh Snodgrass
Validation of an ELISA development kit for apolipoprotein B measurement in dried blood spots Geeta N Eick, Paul Kowal, J Josh Snodgrass Ischemic Cardiovascular Disease Leading cause of death worldwide
More informationCardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study
(28) 32, S11 S16 & 28 Nature Publishing Group All rights reserved 37-6/8 $3. www.nature.com/ijo ORIGINAL ARTICLE Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular
More informationCardiac Disease Screening Lipid Profile
Cardiac Disease Screening Lipid Profile Date of Origin: 04/2003 Last Review Date: 02/27/2019 Effective Date: 03/01/2019 Dates Reviewed: 01/2004, 04/2005, 12/2005, 06/2006, 06/2007, 07/2008, 6/2011, 05/2012,
More information